AZD7762 is a novel checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2, respectively. It significantly prolonged the median time required for tumor volume doubling in response to gemcitabine and radiation. Together, findings suggest that G(2) checkpoint abrogation and homologous recombination repair inhibition both contribute to sensitization by Chk1 inhibition. Furthermore, they support the clinical use of AZD7762 in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer.

June 21, 2017

prudect name : AZD7762 is a novel checkpoint kinase inhibitor with an IC50 of 5 and <10 nM for CHK1 and CHK2, respectively. It significantly prolonged the median time required for tumor volume doubling in response to gemcitabine and radiation. Together, findings suggest that G(2) checkpoint abrogation and homologous recombination repair inhibition both contribute to sensitization by Chk1 inhibition. Furthermore, they support the clinical use of AZD7762 in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer.
AZD7762

Synonyms: CAS NO: 860352-01-8Molecular Formula: C₁₇H₁₉FN₄O₂SMolecular Weight: 362.42Purity: 99%Solubility: In DMSOStorage: −20°C

1092939-17-7 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18496812